Carcinoma, Non-Small-Cell Lung
Conditions
Brief summary
This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.
Interventions
DRUGAtezolizumab
Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
DRUGBevacizumab
Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Life expectancy ≥ 10 months * Histologically or cytologically confirmed stage IIIB, IIIC, or IV non-squamous NSCLC. Patients with tumors of mixed histology are eligible if the major histological component appears to be non-squamous. * No prior treatment for Stage IIIB, IIIC, or IV non-squamous NSCLC, with the following exceptions: Patients with a sensitizing mutation in the EGFR gene must have experienced disease progression or were intolerant to treatment with one or more EGFR TKIs. Patients who have progressed on or were intolerant to first-line osimertinib or other thirdgeneration EGFR TKIs are eligible. Patients who have progressed on or were intolerant to first- or second-generation EGFR TKIs, and who have no evidence of the EGFR T790M mutation after TKI therapy are eligible. Patients who have progressed on or were intolerant to first- or second-generation EGFR TKIs and who have evidence of the T790M mutation must have also progressed on or were intolerant to osimertinib to be eligible. * TKIs approved for treatment of NSCLC discontinued \>7 days prior to enrollment. * Measurable disease per RECIST v1.1. PD-L1 expression of ≥1% as documented through central testing of a representative tumor tissue specimen either from previously obtained archival tumor tissue or tissue obtained from a biopsy at screening * ECOG Performance Status of 0-1 * Adequate hematologic and end-organ function * Negative HIV test at screening * Negative hepatitis B surface antigen (HBsAg) test at screening * Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. The HBV DNA test will be performed only for patients who have a positive total HBcAb test. * Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test. * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs. * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.
Exclusion criteria
* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments * History of leptomeningeal disease * Prior chemotherapy or other systemic therapy for stage IIIB, IIIC, or IV disease * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan * Active tuberculosis * Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina * History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death * Prior allogeneic stem cell or solid organ transplantation * Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab * Current treatment with anti-viral therapy for HBV * Treatment with investigational therapy within 28 days prior to initiation of study treatment * Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies * Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment * Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment * History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins * Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulations * Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab, 6 months after the final dose of bevacizumab * Prior history of hypertensive crisis or hypertensive encephalopathy * Significant vascular disease within 6 months prior to initiation of study treatment * History of Grade ≥ 2 hemoptysis within 1 month prior to enrollment * Evidence of bleeding diathesis or coagulopathy. Current or recent use of aspirin, clopidogrel or treatment with dipyramidole, ticlopidine, or cilostazol * Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes that has not been stable for \> 2 weeks prior to enrollment * History of stroke or transient ischemic attack within 6 months prior to enrollment * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of bevacizumab * History of abdominal or tracheosphageal fistula or gastrointestinal perforation within 6 months prior to enrollment * History of intra-abdominal inflammatory process within 6 months prior to initiation of study treatment, including but not limited to active peptic ulcer disease, diverticulitis,or colitis * Clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding * Evidence of abdominal free air not explained by paracentesis or recent surgical procedure * Proteinuria * Clear tumor infiltration into the thoracic great vessels is seen on imaging * Clear cavitation of pulmonary lesions is seen on imaging
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Baseline up to approximately 10 months | Objective response rate (ORR) was defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Response (TTR) | Baseline up to approximately 2.5 years | Time to response (TTR) was defined as the time from the start of the treatment to the first objective tumor response observed for participants who achieved CR or PR, as determined by the investigator according to RECIST v1.1. |
| Disease Control Rate (DCR) | Baseline up to approximately 2.5 years | Disease control rate (DCR) was defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to RECIST v1.1. |
| Overall Survival (OS) | Baseline until death due to any cause (up to approximately 2.5 years) | OS after enrollment was defined as the time from enrollment to death from any cause. |
| Progression-Free Survival (PFS) | Baseline up to approximately 2.5 years | Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1. |
| PFS Rate at 6 and 12 Months | Baseline to 6 months and 12 months | PFS rate at 6 and 12 months is defined as the percentage of participants who have not experienced disease progression or death from any cause at 6 and 12 months, as determined by the investigator according to RECIST v1.1. |
| OS Rate at 1 and 2 Years | Baseline to 1 and 2 Years | OS rate at 1 and 2 years was defined as the percentage of participants who have not experienced death from any cause at 1 and 2 years. |
| Percentage of Participants With Adverse Events | Baseline up to approximately 2.5 years | Percentage of participants with adverse events. |
| Percentage of Participants With Serious and Non-Serious Immune-Mediated Adverse Events (irAEs) | Baseline up to approximately 2.5 years | Percentage of serious and non-serious immune-mediated adverse events related to atezolizumab treatment. The AESIs were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria. The grading is as follows: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE. |
| Duration of Objective Response (DOR) | Baseline up to approximately 2.5 years | Duration of objective response (DOR) was defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to RECIST v1.1. |
| Disease Control Rate (DCR) According to iRECIST | Baseline up to 2 years and approximately 5 months | Disease control rate (DCR) is defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to modified RECIST v1.1 (iRECIST). |
| Duration of Objective Response (DOR) According to iRECIST | Baseline up to approximately 2.5 years | Duration of objective response (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST). |
| Progression-Free Survival (PFS) According to iRECIST | Baseline up to approximately 2.5 years | Progression-free survival (PFS) is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST). |
| Progression-Free Survival (PFS) Rate at 12 Months According to iRECIST | Baseline up to approximately 12 months | Progression-free survival (PFS) rate is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first at 12 months, as determined by the investigator according to modified RECIST v1.1 (iRECIST). |
| Time to Deterioation (TTD) Using EORTC | Baselsine up to approximately 1 year | Time to deterioration (TTD) using European Organization for Research and treatment of Cancer (EORTC) Quality-of-life Questionnaire Core 30 (QLQ C30) and its Lung Cancer Module (QLQ LC13) is defined as the time from baseline to the first time the patient's score shows a \>=10 points increase above baseline in any of the following EORTC-transformed symptom subscale scores (whichever occurs first): cough, dyspnoea (single item), dyspnoea (multi-item subscale), chest pain, or arm/shoulder pain, whichever occurred first. Scores ranged from 0-10. A higher score represented more severe symptoms. |
| Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Baseline up to approximately 1 year | The 30-item EORTC QLQ-C30 version 3 is composed by five multi-item function scales (physical, role, cognitive, emotional, and social), three multi-item symptom scales (fatigue, nausea and vomiting, and pain), six single-item symptom scales (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), and a two-item global quality of life scale. All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for the functional and general health areas represent better functional status and quality of life. Higher scores for the symptom scales represent more symptoms or problems (poor quality of life). A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores. |
| Change From Baseline in Lung Cancer Related Symptoms | Baseline up to approximately 1 year | The EORTC QLQ-LC13 is a specific module for lung cancer. It consists of 13 items covering lung cancer symptoms (dyspnoea, coughing, hemoptysis, pain in chest, pain in arm or shoulder and pain in other parts) and the side effects of chemo- and radiotherapy (alopecia, peripheral neuropathy, sore mouth, and dysphagia), which are divided into 10 fields, all are symptom types. All EORTC symptom scores are linearly transformed so that each score has a range of 0-100. A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores. |
| Objective Response Rate (ORR) According to iRECIST | Baseline up to approximately 2.5 years | Objective response rate (ORR) is defined as the proportion of participants with a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to Modified RECIST v1.1 (iRECIST). |
Countries
China
Participant flow
Recruitment details
This study was conducted at multiple investigational sites in China
Participants by arm
| Arm | Count |
|---|---|
| Atezolizumab Plus Bevacizumab Participants will receive atezolizumab plus bevacizumab intravenously on Day 1 of each cycle. Treatment will continue until progressive disease, unacceptable toxicity, or death. | 23 |
| Total | 23 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 17 |
| Overall Study | Lost to Follow-up | 1 |
| Overall Study | Study terminated by sponsor | 5 |
Baseline characteristics
| Characteristic | Atezolizumab Plus Bevacizumab |
|---|---|
| Age, Continuous | 59.8 Years STANDARD_DEVIATION 10.07 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 23 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Sex: Female, Male Female | 13 Participants |
| Sex: Female, Male Male | 10 Participants |
| Smoking History Current | 0 Participants |
| Smoking History Never | 16 Participants |
| Smoking History Previous | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 17 / 23 |
| other Total, other adverse events | 23 / 23 |
| serious Total, serious adverse events | 4 / 23 |
Outcome results
Primary
Objective Response Rate (ORR)
Objective response rate (ORR) was defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
Time frame: Baseline up to approximately 10 months
Population: The evaluable population included all enrolled participants who received any amount of study treatment, had baseline and at least one post-baseline efficacy measurement.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Objective Response Rate (ORR) | 18.2 Percentage of Participants |
Secondary
Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status
The 30-item EORTC QLQ-C30 version 3 is composed by five multi-item function scales (physical, role, cognitive, emotional, and social), three multi-item symptom scales (fatigue, nausea and vomiting, and pain), six single-item symptom scales (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), and a two-item global quality of life scale. All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for the functional and general health areas represent better functional status and quality of life. Higher scores for the symptom scales represent more symptoms or problems (poor quality of life). A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.
Time frame: Baseline up to approximately 1 year
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment. The number of participants in the FAS with a non-missing baseline PRO assessment are presented. As each participant had different treatment cycles, this resulted in different numbers of participants analyzed per cycle.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 02 | 0.833 Units on a scale | Standard Deviation 28.855 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 06 | -16.667 Units on a scale | Standard Deviation 23.987 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 11 | -6.667 Units on a scale | Standard Deviation 6.667 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Baseline | 81.061 Units on a scale | Standard Deviation 22.593 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 03 | -7.292 Units on a scale | Standard Deviation 28.525 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 15 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Baseline | 76.894 Units on a scale | Standard Deviation 23.561 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 02 | -2.083 Units on a scale | Standard Deviation 18.312 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 09 | -5.556 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 15 | -8.333 Units on a scale | Standard Deviation 11.785 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 03 | 1.042 Units on a scale | Standard Deviation 25.436 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 06 | 12.500 Units on a scale | Standard Deviation 17.252 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global Quality of Life (QoL) - Baseline | 53.409 Units on a scale | Standard Deviation 28.132 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 03 | -0.521 Units on a scale | Standard Deviation 27.465 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 04 | -6.250 Units on a scale | Standard Deviation 28.007 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 05 | -15.625 Units on a scale | Standard Deviation 24.975 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 07 | -23.611 Units on a scale | Standard Deviation 20.012 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 08 | -20.833 Units on a scale | Standard Deviation 43.381 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 09 | -36.111 Units on a scale | Standard Deviation 4.811 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 10 | -22.222 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 11 | -30.556 Units on a scale | Standard Deviation 4.811 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 12 | -27.778 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 13 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 14 | -25.000 Units on a scale | Standard Deviation 11.785 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Treatment Cycle 15 | -33.333 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Follow Up | -16.667 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Follow Up 2 | -16.667 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Global QoL - Follow Up 3 | -25.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Baseline | 79.091 Units on a scale | Standard Deviation 15.437 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 02 | -5.667 Units on a scale | Standard Deviation 20.207 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 03 | -4.167 Units on a scale | Standard Deviation 15.49 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 04 | -0.556 Units on a scale | Standard Deviation 11.177 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 05 | -1.667 Units on a scale | Standard Deviation 14.584 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 06 | -0.833 Units on a scale | Standard Deviation 10.947 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 07 | -6.667 Units on a scale | Standard Deviation 10.328 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 08 | -8.889 Units on a scale | Standard Deviation 10.037 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 09 | -15.556 Units on a scale | Standard Deviation 16.777 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 10 | -6.667 Units on a scale | Standard Deviation 6.667 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 12 | -13.333 Units on a scale | Standard Deviation 17.638 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 13 | -6.667 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 14 | -6.667 Units on a scale | Standard Deviation 9.428 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Treatment Cycle 15 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Physical Functioning - Follow Up 2 | 6.667 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 02 | -7.500 Units on a scale | Standard Deviation 32.307 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 04 | -4.167 Units on a scale | Standard Deviation 14.434 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 05 | -4.167 Units on a scale | Standard Deviation 21.362 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 06 | -4.167 Units on a scale | Standard Deviation 14.773 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 07 | 0.000 Units on a scale | Standard Deviation 21.082 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 08 | -8.333 Units on a scale | Standard Deviation 25.276 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 09 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 10 | -11.111 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 11 | 0 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 12 | -5.556 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Role Functioning - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 03 | -0.521 Units on a scale | Standard Deviation 20.965 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 04 | 0.000 Units on a scale | Standard Deviation 28.868 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 05 | -5.208 Units on a scale | Standard Deviation 23.544 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 06 | -4.167 Units on a scale | Standard Deviation 19.92 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 07 | -12.500 Units on a scale | Standard Deviation 22.822 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 08 | -8.333 Units on a scale | Standard Deviation 15.811 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 09 | -13.889 Units on a scale | Standard Deviation 17.347 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 10 | -16.667 Units on a scale | Standard Deviation 14.434 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 11 | -19.444 Units on a scale | Standard Deviation 26.788 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 12 | -2.778 Units on a scale | Standard Deviation 12.729 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 14 | 4.167 Units on a scale | Standard Deviation 5.893 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Treatment Cycle 15 | 4.167 Units on a scale | Standard Deviation 5.893 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Emotional Functioning - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Baseline | 79.545 Units on a scale | Standard Deviation 17.006 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 02 | 1.667 Units on a scale | Standard Deviation 17.014 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 03 | -2.083 Units on a scale | Standard Deviation 14.751 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 04 | 1.389 Units on a scale | Standard Deviation 15.006 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 05 | -8.333 Units on a scale | Standard Deviation 17.817 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 06 | 2.083 Units on a scale | Standard Deviation 13.909 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 07 | -16.667 Units on a scale | Standard Deviation 25.82 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 08 | -11.111 Units on a scale | Standard Deviation 17.213 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 10 | 5.556 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 11 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 12 | -5.556 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Cognitive Functioning - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Baseline | 67.424 Units on a scale | Standard Deviation 28.857 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 02 | -3.333 Units on a scale | Standard Deviation 30.874 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 04 | -1.389 Units on a scale | Standard Deviation 28.831 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 05 | 0.000 Units on a scale | Standard Deviation 34.503 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 06 | 2.083 Units on a scale | Standard Deviation 32.657 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 07 | -13.889 Units on a scale | Standard Deviation 24.553 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 08 | -11.111 Units on a scale | Standard Deviation 25.092 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 09 | -11.111 Units on a scale | Standard Deviation 25.459 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 10 | -11.111 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 11 | -11.111 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 12 | -5.556 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 13 | 16.667 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 14 | -8.333 Units on a scale | Standard Deviation 35.355 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Treatment Cycle 15 | -8.333 Units on a scale | Standard Deviation 35.355 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Social Functioning - Follow Up 3 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Baseline | 34.343 Units on a scale | Standard Deviation 22.979 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 02 | 3.889 Units on a scale | Standard Deviation 25.814 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 03 | 8.333 Units on a scale | Standard Deviation 20.488 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 04 | 5.556 Units on a scale | Standard Deviation 24.845 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 05 | 8.333 Units on a scale | Standard Deviation 17.568 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 06 | 9.722 Units on a scale | Standard Deviation 13.849 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 07 | 9.259 Units on a scale | Standard Deviation 12.989 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 08 | 16.667 Units on a scale | Standard Deviation 18.257 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 09 | 14.815 Units on a scale | Standard Deviation 16.973 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 10 | 14.815 Units on a scale | Standard Deviation 16.973 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 11 | 18.519 Units on a scale | Standard Deviation 32.075 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 12 | 7.407 Units on a scale | Standard Deviation 23.13 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Treatment Cycle 15 | 5.556 Units on a scale | Standard Deviation 7.857 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Follow Up 2 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Fatigue - Follow Up 3 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Baseline | 6.818 Units on a scale | Standard Deviation 15.985 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 02 | 2.500 Units on a scale | Standard Deviation 9.786 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 03 | 3.125 Units on a scale | Standard Deviation 12.5 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 04 | 0.000 Units on a scale | Standard Deviation 7.107 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 05 | 2.083 Units on a scale | Standard Deviation 5.893 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 06 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 07 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 08 | 2.778 Units on a scale | Standard Deviation 6.804 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 09 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 10 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 11 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 12 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Treatment Cycle 15 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Nausea and Vomiting - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain - Baseline | 31.061 Units on a scale | Standard Deviation 24.286 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 02 | -2.500 Units on a scale | Standard Deviation 23.116 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 03 | -4.167 Units on a scale | Standard Deviation 21.517 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 04 | -1.389 Units on a scale | Standard Deviation 18.06 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 05 | 6.250 Units on a scale | Standard Deviation 23.465 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 06 | 4.167 Units on a scale | Standard Deviation 24.801 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 07 | 5.556 Units on a scale | Standard Deviation 17.213 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 08 | 16.667 Units on a scale | Standard Deviation 29.814 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 09 | 27.778 Units on a scale | Standard Deviation 34.694 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 10 | 5.556 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 11 | 22.222 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 12 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 14 | 8.333 Units on a scale | Standard Deviation 11.785 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain -Treatment Cycle 15 | 16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain - Follow Up 2 | -16.667 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Pain - Follow Up 3 | -16.667 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Baseline | 25.758 Units on a scale | Standard Deviation 22.845 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 02 | 3.333 Units on a scale | Standard Deviation 30.397 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 03 | 6.250 Units on a scale | Standard Deviation 21.837 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 04 | 2.778 Units on a scale | Standard Deviation 17.164 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 05 | 8.333 Units on a scale | Standard Deviation 15.43 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 07 | 5.556 Units on a scale | Standard Deviation 13.608 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 08 | 11.111 Units on a scale | Standard Deviation 17.213 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 09 | 33.333 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 10 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 11 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 12 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 13 | 33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 14 | 16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Treatment Cycle 15 | 16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Dyspnoea - Follow Up 3 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Baseline | 27.273 Units on a scale | Standard Deviation 22.15 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 02 | 5.000 Units on a scale | Standard Deviation 29.17 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 03 | 6.250 Units on a scale | Standard Deviation 27.806 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 04 | 0.000 Units on a scale | Standard Deviation 24.618 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 05 | 4.167 Units on a scale | Standard Deviation 27.817 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 06 | 8.333 Units on a scale | Standard Deviation 29.547 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 07 | 5.556 Units on a scale | Standard Deviation 25.092 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 08 | 0.000 Units on a scale | Standard Deviation 29.814 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 09 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 10 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 11 | 22.222 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 12 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Treatment Cycle 15 | 16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Insomnia - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Baseline | 27.273 Units on a scale | Standard Deviation 24.422 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 02 | -1.667 Units on a scale | Standard Deviation 29.568 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 03 | -6.250 Units on a scale | Standard Deviation 27.806 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 04 | 2.778 Units on a scale | Standard Deviation 22.285 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 05 | 4.167 Units on a scale | Standard Deviation 21.362 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 06 | 4.167 Units on a scale | Standard Deviation 21.362 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 07 | -5.556 Units on a scale | Standard Deviation 13.608 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 08 | 0.000 Units on a scale | Standard Deviation 21.082 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 09 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 10 | 0.000 Units on a scale | Standard Deviation 33.333 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 11 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 12 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 14 | 16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Treatment Cycle 15 | 16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Follow Up | 33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Appetite Loss - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Baseline | 15.152 Units on a scale | Standard Deviation 16.988 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 02 | -3.333 Units on a scale | Standard Deviation 23.939 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 03 | 6.250 Units on a scale | Standard Deviation 30.353 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 04 | -5.556 Units on a scale | Standard Deviation 12.975 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 05 | -4.167 Units on a scale | Standard Deviation 21.362 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 06 | -8.333 Units on a scale | Standard Deviation 15.43 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 07 | -5.556 Units on a scale | Standard Deviation 13.608 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 08 | -5.556 Units on a scale | Standard Deviation 13.608 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 09 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 10 | 0.000 Units on a scale | Standard Deviation 33.333 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 11 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 12 | 0.000 Units on a scale | Standard Deviation 33.333 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 13 | 33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Treatment Cycle 15 | 16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Constipation - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Baseline | 9.091 Units on a scale | Standard Deviation 18.349 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 02 | -3.333 Units on a scale | Standard Deviation 18.417 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 03 | -4.167 Units on a scale | Standard Deviation 20.638 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 04 | -8.333 Units on a scale | Standard Deviation 20.719 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 05 | -4.167 Units on a scale | Standard Deviation 11.785 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 06 | -4.167 Units on a scale | Standard Deviation 11.785 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 07 | -5.556 Units on a scale | Standard Deviation 13.608 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 08 | 0.000 Units on a scale | Standard Deviation 21.082 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 09 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 10 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 11 | 0.000 Units on a scale | Standard Deviation 33.333 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 12 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Treatment Cycle 15 | 16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Diarrhoea - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Baseline | 60.606 Units on a scale | Standard Deviation 33.549 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 02 | -8.333 Units on a scale | Standard Deviation 26.213 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 03 | -10.417 Units on a scale | Standard Deviation 26.44 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 04 | -11.111 Units on a scale | Standard Deviation 25.95 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 05 | -16.667 Units on a scale | Standard Deviation 25.198 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 06 | -33.333 Units on a scale | Standard Deviation 30.861 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 07 | -27.778 Units on a scale | Standard Deviation 32.773 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 08 | -22.222 Units on a scale | Standard Deviation 40.369 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 09 | -22.222 Units on a scale | Standard Deviation 50.918 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 10 | -22.222 Units on a scale | Standard Deviation 50.918 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 11 | -11.111 Units on a scale | Standard Deviation 50.918 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 12 | -11.111 Units on a scale | Standard Deviation 50.918 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 13 | -66.667 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Treatment Cycle 15 | -16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Follow Up 2 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status | Financial Difficulties - Follow Up 3 | -33.333 Units on a scale | — |
Secondary
Change From Baseline in Lung Cancer Related Symptoms
The EORTC QLQ-LC13 is a specific module for lung cancer. It consists of 13 items covering lung cancer symptoms (dyspnoea, coughing, hemoptysis, pain in chest, pain in arm or shoulder and pain in other parts) and the side effects of chemo- and radiotherapy (alopecia, peripheral neuropathy, sore mouth, and dysphagia), which are divided into 10 fields, all are symptom types. All EORTC symptom scores are linearly transformed so that each score has a range of 0-100. A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.
Time frame: Baseline up to approximately 1 year
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment. The number of participants in the FAS with a non-missing baseline PRO assessment are presented. As each participant had different treatment cycles, this resulted in different numbers of participants analyzed per cycle.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 04 | -13.889 Units on a scale | Standard Deviation 22.285 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 14 | -16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Baseline | 22 Units on a scale | Standard Deviation 27.273 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 11 | 11.111 Units on a scale | Standard Deviation 50.918 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 12 | 11.111 Units on a scale | Standard Deviation 50.918 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Baseline | 34.343 Units on a scale | Standard Deviation 20.26 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 02 | -5.556 Units on a scale | Standard Deviation 18.557 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 03 | -2.778 Units on a scale | Standard Deviation 20.488 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 04 | -4.630 Units on a scale | Standard Deviation 16.723 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 05 | -2.778 Units on a scale | Standard Deviation 19.473 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 06 | 5.556 Units on a scale | Standard Deviation 16.798 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 07 | 0.000 Units on a scale | Standard Deviation 14.055 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 08 | 0.000 Units on a scale | Standard Deviation 22.222 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 09 | 11.111 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 10 | 7.407 Units on a scale | Standard Deviation 16.973 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 11 | 7.407 Units on a scale | Standard Deviation 6.415 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 12 | 7.407 Units on a scale | Standard Deviation 16.973 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Treatment Cycle 13 | 11.111 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Follow Up | -22.222 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Follow Up 2 | -22.222 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dyspnoea - Follow Up 3 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Baseline | 37.879 Units on a scale | Standard Deviation 31.363 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 02 | 1.667 Units on a scale | Standard Deviation 25.305 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 03 | 10.417 Units on a scale | Standard Deviation 23.472 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 04 | 0.000 Units on a scale | Standard Deviation 14.213 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 05 | 4.167 Units on a scale | Standard Deviation 21.362 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 06 | 16.667 Units on a scale | Standard Deviation 30.861 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 07 | 0.000 Units on a scale | Standard Deviation 21.082 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 08 | 11.111 Units on a scale | Standard Deviation 34.427 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 09 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 10 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 11 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 12 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 47.14 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Treatment Cycle 15 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Follow Up | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Follow Up 2 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Coughing - Follow Up 3 | -66.667 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Baseline | 4.545 Units on a scale | Standard Deviation 15.585 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 02 | -1.667 Units on a scale | Standard Deviation 13.134 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 03 | -2.083 Units on a scale | Standard Deviation 8.333 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 04 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 05 | -4.167 Units on a scale | Standard Deviation 11.785 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 06 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 07 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 08 | 11.111 Units on a scale | Standard Deviation 27.217 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 09 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 10 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 11 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 12 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Treatment Cycle 15 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Hemoptysis - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Baseline | 3.030 Units on a scale | Standard Deviation 9.808 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 02 | 6.667 Units on a scale | Standard Deviation 20.52 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 03 | 4.167 Units on a scale | Standard Deviation 20.638 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 04 | 0.000 Units on a scale | Standard Deviation 20.101 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 05 | 4.167 Units on a scale | Standard Deviation 11.785 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 06 | -4.167 Units on a scale | Standard Deviation 11.785 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 07 | 5.556 Units on a scale | Standard Deviation 13.608 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 08 | 5.556 Units on a scale | Standard Deviation 13.608 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 09 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 10 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 11 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 12 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Treatment Cycle 15 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Sore mouth - Follow Up 3 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Baseline | 10.606 Units on a scale | Standard Deviation 15.891 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 02 | 5.000 Units on a scale | Standard Deviation 24.839 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 03 | 0.000 Units on a scale | Standard Deviation 12.172 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 04 | -2.778 Units on a scale | Standard Deviation 9.623 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 05 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 06 | -8.333 Units on a scale | Standard Deviation 15.43 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 07 | -5.556 Units on a scale | Standard Deviation 13.608 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 08 | -5.556 Units on a scale | Standard Deviation 13.608 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 09 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 10 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 11 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 12 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 14 | -16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Treatment Cycle 15 | -16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Follow Up | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Follow Up 2 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Dysphagia - Follow Up 3 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Baseline | 9.091 Units on a scale | Standard Deviation 18.349 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 02 | 6.5667 Units on a scale | Standard Deviation 23.195 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 03 | 4.167 Units on a scale | Standard Deviation 16.667 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 04 | 8.333 Units on a scale | Standard Deviation 15.076 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 05 | 12.500 Units on a scale | Standard Deviation 17.252 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 06 | 12.500 Units on a scale | Standard Deviation 17.252 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 07 | 11.111 Units on a scale | Standard Deviation 17.213 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 08 | 11.111 Units on a scale | Standard Deviation 17.213 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 09 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 10 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 11 | 11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 12 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 14 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Treatment Cycle 15 | 0.000 Units on a scale | Standard Deviation 0 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Follow Up | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Peripheral neuropathy - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia -Baseline | 16.667 Units on a scale | Standard Deviation 26.726 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 02 | -3.333 Units on a scale | Standard Deviation 18.417 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 03 | -12.500 Units on a scale | Standard Deviation 29.502 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 05 | -8.333 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 06 | -12.500 Units on a scale | Standard Deviation 24.801 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 07 | -5.556 Units on a scale | Standard Deviation 25.092 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 08 | -5.556 Units on a scale | Standard Deviation 25.092 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 09 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 10 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 11 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 12 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Treatment Cycle 15 | -16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Follow Up | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Follow Up 2 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Alopecia - Follow Up 3 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Baseline | 31.818 Units on a scale | Standard Deviation 29.951 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 02 | 1.667 Units on a scale | Standard Deviation 29.568 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 03 | 0.000 Units on a scale | Standard Deviation 29.814 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 04 | 2.778 Units on a scale | Standard Deviation 22.285 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 05 | 4.167 Units on a scale | Standard Deviation 33.034 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 06 | 0.000 Units on a scale | Standard Deviation 25.198 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 07 | 5.556 Units on a scale | Standard Deviation 32.773 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 08 | -5.556 Units on a scale | Standard Deviation 25.092 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 09 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 10 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 11 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 12 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 14 | -16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Treatment Cycle 15 | -16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Follow Up | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Follow Up 2 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in chest - Follow Up 3 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 02 | -6.667 Units on a scale | Standard Deviation 31.715 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 03 | -12.500 Units on a scale | Standard Deviation 36.26 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 04 | -8.333 Units on a scale | Standard Deviation 35.176 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 05 | -4.167 Units on a scale | Standard Deviation 45.207 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 06 | -4.167 Units on a scale | Standard Deviation 41.547 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 07 | 5.556 Units on a scale | Standard Deviation 25.092 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 08 | 22.222 Units on a scale | Standard Deviation 40.369 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 09 | 33.333 Units on a scale | Standard Deviation 57.735 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 10 | 11.111 Units on a scale | Standard Deviation 50.918 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 14 | 50.000 Units on a scale | Standard Deviation 70.711 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder -Treatment Cycle 15 | 16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder - Follow Up | 33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder - Follow Up 2 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in arm or shoulder - Follow Up 3 | 33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Baseline | 25.758 Units on a scale | Standard Deviation 28.971 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 02 | -3.333 Units on a scale | Standard Deviation 23.939 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 03 | -2.083 Units on a scale | Standard Deviation 22.669 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 04 | 2.778 Units on a scale | Standard Deviation 22.285 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 05 | 16.667 Units on a scale | Standard Deviation 25.198 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 06 | -4.167 Units on a scale | Standard Deviation 21.362 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 07 | -5.556 Units on a scale | Standard Deviation 25.092 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 08 | 5.556 Units on a scale | Standard Deviation 32.773 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 09 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 10 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 11 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 12 | -11.111 Units on a scale | Standard Deviation 19.245 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 13 | 0.000 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 14 | -16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Treatment Cycle 15 | -16.667 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Follow Up | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Follow Up 2 | -33.333 Units on a scale | — |
| Atezolizumab Plus Bevacizumab | Change From Baseline in Lung Cancer Related Symptoms | Pain in other parts - Follow Up 3 | -33.333 Units on a scale | — |
Secondary
Disease Control Rate (DCR)
Disease control rate (DCR) was defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to approximately 2.5 years
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Disease Control Rate (DCR) | 65.2 Percentage of Participants |
Secondary
Disease Control Rate (DCR) According to iRECIST
Disease control rate (DCR) is defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to 2 years and approximately 5 months
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Disease Control Rate (DCR) According to iRECIST | 65.2 Percentage of Participants |
Secondary
Duration of Objective Response (DOR)
Duration of objective response (DOR) was defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to approximately 2.5 years
Population: The full analysis set (FAS) population included all enrolled participants who received any amount of at least one dose of any study treatment. The analysis population for this outcome measures included participants with a confirmed response (CR or PR).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Duration of Objective Response (DOR) | 6.36 Months |
Secondary
Duration of Objective Response (DOR) According to iRECIST
Duration of objective response (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to approximately 2.5 years
Population: The full analysis set (FAS) population included all enrolled participants who received any amount of at least one dose of any study treatment. The analysis population for this outcome measures included participants with a confirmed response (iCR or iPR).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Duration of Objective Response (DOR) According to iRECIST | 6.36 Months |
Secondary
Objective Response Rate (ORR) According to iRECIST
Objective response rate (ORR) is defined as the proportion of participants with a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to Modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to approximately 2.5 years
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Objective Response Rate (ORR) According to iRECIST | 17.4 Percentage of Participants |
Secondary
OS Rate at 1 and 2 Years
OS rate at 1 and 2 years was defined as the percentage of participants who have not experienced death from any cause at 1 and 2 years.
Time frame: Baseline to 1 and 2 Years
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Atezolizumab Plus Bevacizumab | OS Rate at 1 and 2 Years | 1 year | 52.17 Percentage of participants |
| Atezolizumab Plus Bevacizumab | OS Rate at 1 and 2 Years | 2 years | 30.43 Percentage of participants |
Secondary
Overall Survival (OS)
OS after enrollment was defined as the time from enrollment to death from any cause.
Time frame: Baseline until death due to any cause (up to approximately 2.5 years)
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Overall Survival (OS) | 14.06 Months |
Secondary
Percentage of Participants With Adverse Events
Percentage of participants with adverse events.
Time frame: Baseline up to approximately 2.5 years
Population: The safety population is defined as all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Percentage of Participants With Adverse Events | 23 Participants |
Secondary
Percentage of Participants With Serious and Non-Serious Immune-Mediated Adverse Events (irAEs)
Percentage of serious and non-serious immune-mediated adverse events related to atezolizumab treatment. The AESIs were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria. The grading is as follows: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE.
Time frame: Baseline up to approximately 2.5 years
Population: The safety population is defined as all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atezolizumab Plus Bevacizumab | Percentage of Participants With Serious and Non-Serious Immune-Mediated Adverse Events (irAEs) | Non-serious irAEs | 7 Participants |
| Atezolizumab Plus Bevacizumab | Percentage of Participants With Serious and Non-Serious Immune-Mediated Adverse Events (irAEs) | Serious irAEs | 1 Participants |
Secondary
PFS Rate at 6 and 12 Months
PFS rate at 6 and 12 months is defined as the percentage of participants who have not experienced disease progression or death from any cause at 6 and 12 months, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline to 6 months and 12 months
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Atezolizumab Plus Bevacizumab | PFS Rate at 6 and 12 Months | 6 months | 13.91 Percentage of participants |
| Atezolizumab Plus Bevacizumab | PFS Rate at 6 and 12 Months | 12 months | 4.64 Percentage of participants |
Secondary
Progression-Free Survival (PFS)
Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to approximately 2.5 years
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Progression-Free Survival (PFS) | 2.76 Months |
Secondary
Progression-Free Survival (PFS) According to iRECIST
Progression-free survival (PFS) is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to approximately 2.5 years
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Progression-Free Survival (PFS) According to iRECIST | 2.76 Months |
Secondary
Progression-Free Survival (PFS) Rate at 12 Months According to iRECIST
Progression-free survival (PFS) rate is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first at 12 months, as determined by the investigator according to modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to approximately 12 months
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab Plus Bevacizumab | Progression-Free Survival (PFS) Rate at 12 Months According to iRECIST | 4.64 Months |
Secondary
Time to Deterioation (TTD) Using EORTC
Time to deterioration (TTD) using European Organization for Research and treatment of Cancer (EORTC) Quality-of-life Questionnaire Core 30 (QLQ C30) and its Lung Cancer Module (QLQ LC13) is defined as the time from baseline to the first time the patient's score shows a \>=10 points increase above baseline in any of the following EORTC-transformed symptom subscale scores (whichever occurs first): cough, dyspnoea (single item), dyspnoea (multi-item subscale), chest pain, or arm/shoulder pain, whichever occurred first. Scores ranged from 0-10. A higher score represented more severe symptoms.
Time frame: Baselsine up to approximately 1 year
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment. The number of participants in the FAS with a non-missing baseline PRO assessment are presented.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Atezolizumab Plus Bevacizumab | Time to Deterioation (TTD) Using EORTC | Cough | NA Months |
| Atezolizumab Plus Bevacizumab | Time to Deterioation (TTD) Using EORTC | Dyspnoea (single-item Q33) | NA Months |
| Atezolizumab Plus Bevacizumab | Time to Deterioation (TTD) Using EORTC | Dyspnoea (single-item Q34) | NA Months |
| Atezolizumab Plus Bevacizumab | Time to Deterioation (TTD) Using EORTC | Dyspnoea (single-item Q35) | NA Months |
| Atezolizumab Plus Bevacizumab | Time to Deterioation (TTD) Using EORTC | Dyspnoea (multi-item) | NA Months |
| Atezolizumab Plus Bevacizumab | Time to Deterioation (TTD) Using EORTC | Chest pain | NA Months |
| Atezolizumab Plus Bevacizumab | Time to Deterioation (TTD) Using EORTC | Arm/shoulder pain | NA Months |
Secondary
Time to Response (TTR)
Time to response (TTR) was defined as the time from the start of the treatment to the first objective tumor response observed for participants who achieved CR or PR, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to approximately 2.5 years
Population: The FAS population included all enrolled participants who received any amount of at least one dose of any study treatment. The analysis population for this outcome measures included participants with a confirmed response (CR or PR).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Atezolizumab Plus Bevacizumab | Time to Response (TTR) | 1.577 Months | Standard Deviation 0.49 |